Ophthalmic formulations of cetirizine and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9750684
APP PUB NO 20160106666A1
SERIAL NO

14982258

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NICOX OPHTHALMICS INC4721 EMPEROR BLVD SUITE 260 DURHAM NC 27703

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Abelson, Mark Barry Andover, US 17 108
Chapin, Matthew J Amesbury, US 25 284
Gomes, Paul Andover, US 12 96
Minno, George Windham, US 30 306
Nice, Jackie Medford, US 13 133

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 5, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 5, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00